


ZD4054

ENTHUSE M1c

In metastatic, castrate-resistant prostate cancer

A Phase III randomized, double-blinded, multicenter study in patients with metastatic, castrate-resistant prostate cancer with progressive disease (defined by rising serum prostate-specific antigen (PSA) levels despite medical or surgical castration)



Purpose: To assess the efficacy and safety of ZD4054 + docetaxel versus placebo + docetaxel in improving overall survival

Primary endpoint: Overall survival

Secondary endpoints: Progression-free survival, safety and tolerability, PSA progression, pain progression, quality of life

Participating countries: Argentina | Australia | Brazil | Canada | Czech Republic | Finland | France | Germany | Hungary | India | Italy | Republic of Korea | Poland | Portugal | Netherlands | Norway | Peru | Serbia | Singapore | Romania | Russian Federation | South Africa | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States

ZD4054 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.

For more information,
please contact:

Cancer Study Locator service, sponsored by
AstraZeneca at 1-877-400-4656
Or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov

AstraZeneca 

AstraZeneca Pharmaceuticals, LP
Wilmington, Delaware
www.astrazeneca.com